Multiple sclerosis cerebrospinal fluid biomarkers

Disease Markers

Volumn 22, Issue 4, 2006, Pages 187-196

  Giovannoni, Gavin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Glatiramer acetate neutralizing antibodies; Immune tolerance; Interferon beta; Multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT PROTEIN;

ALLERGIC ENCEPHALITIS; ASTROCYTE; BIOASSAY; CELL ACTIVATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONFERENCE PAPER; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; GLIOSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REMYELINIZATION; SAMPLING;

EID: 33751114983     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/509476     Document Type: Conference Paper

References (65)

1. M.S. Freedman, E.J. Thompson, F. Deisenhammer, G. Giovannoni, G. Grimsley, G. Keir, S. Ohman, M.K. Racke, M. Sharief, C.J. Sindic, F. Sellebjerg and W.W. Tourtellotte, Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement, Archives of Neurology 62 (2005), 865-870.
2. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion and G.M. Clark, REporting recommendations for tumour MARKer prognostic studies (REMARK), Briish Journal of Cancer (2005), in press.
3. E. Floyd and T.M. McShane, Development and use of biomarkers in oncology drug development, Toxicology and Pathology 32(Suppl 1) (2004), 106-115.
4. R.A. Marrie, Environmental risk factors in multiple sclerosis aetiology, Lancet Neurology 3 (2004), 709-718.
5. F.J. Flier and P.F.V. Robbe, Nosology and causal necessity; the relation between defining a disease and discovering its necessary cause, Theor Med Bioeth 20 (1999), 577-588.
6. W.I. McDonald, A. Compston, G. Edn, D. Goodkin, H.P. Hartung, F.D. Lublin, H.F. McFarland, D.W. Paty, C.H. Polman, S.C. Reingold, M. Sandberg-Wollheim, W. Sibley, A. Thompson, S. van den Noort, B.Y. Weinshenker and J.S. Wolinsky, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of Neurology 50 (2001), 121-127.
7. M. Andersson, J. Alvarez-Cermeno, G. Bernardi, I. Cogato, P. Fredman, J. Frederiksen, S. Fredrikson, P. Gallo, L.M. Grimaldi and M. Gronning, Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report, Journal of Neurology, Neurosurgery and Psychiatry 57 (1994), 897-902.
8. H. Link and G. Tibbling, Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis, Scandinavian Journal of Clinical and Laboratory Investigation 37 (1977), 397-401.
9. G. Giovannoni, B. Kieseier and H.P. Hartung, Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis, Journal of Neurology, Neurosurgery and Psychiatry 64(Suppl 1) (1998), S31-S36.
10. D.A. Hafler, J.M. Slavik, D.E. Anderson, K.C. O'Connor, P. De Jager and C. Baecher-Allan, Multiple sclerosis, Immunological Review 204 (2005), 208-231.
11. D.H. Gilden, Infectious causes of multiple sclerosis, Lancet Neurology 4 (2005), 195-202.
12. D.G. Altman and J.M. Bland, Measuremet in medicine: the analysis of method comparison studies, Statistician 32 (1983), 307-317.
13. E. Lester, The clinical value of glycated haemoglobin and glycated plasma proteins, Annals of Clinical Biochemistry 26(Pt 3) (1989), 213-219.
14. E.J. Thompson, Cerebrospinal fluid, Journal of Neurology, Neurosurgery and Psychiatry 59 (1995), 349-357.
15. C. Nilsson, F. Stahlberg, C. Thomsen, O. Henriksen, M. Herning and C. Owman, Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging, Am J Physiol 262 (1992), R20-R24.
16. K. Blennow, P. Fredman, A. Wallin, C.G. Gottfries, G. Langstrom and L. Svennerholm, Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio, European Neurology 33 (1993), 126-128.
17. J.L. Frederiksen, Can CSF predict the course of optic neuritis? Multiple Sclerosis 4 (1998), 132-135.
18. C. Jacobi, H. Reiber and K. Felgenhauer, The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid, Journal of Neurology 233 (1986), 358-361.
19. P. Rieckmann, B. Altenhofen, A. Riegel, B. Kallmann and K. Felgenhauer, Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis, Multiple Sclerosis 4 (1998), 178-182.
20. J.C. Hobart, A. Riazi, D.L. Lamping, R. Fitzpatrick and A.J. Thompson, Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome, Health Technol Assess 8 (2004), (iii) 1-iii, 48.
21. P.A. Brex, O. Ciccarelli, J.I. O'Riordan, M. Sailer, A.J. Thompson and D.H. Miller, A longitudinal study of abnormalities on MRI and disability from multiple sclerosis, New England Journal of Medicine 346 (2002), 158-164.
22. B. Bielekova and R. Martin, Development of biomarkers in multiple sclerosis, Brain 127 (2004), 1463-1478.
23. M. Gironi, A. Bergami, E. Brambilla, F. Ruffini, R. Furlan, G. Comi and G. Martino, Immunological markers in multiple sclerosis, Neurological Science 21 (2000), S871-S875.
24. A. Uccelli, E. Pedemonte, E. Narciso and G. Mancardi, Biological markers of the inflammatory phase of multiple sclerosis, Neurological Science 24(Suppl 5) (2003), S271-S274.
25. L.P. Weiner, N.J. Kachuck, W. Gilmore and B. Lund, Immunological aspects of secondary progressive multiple sclerosis, Multiple Sclerosis 8 (2002), 83-84.
26. A.J. Thompson, C.H. Polman, D.H. Miller, W.I. McDonald, B. Brochet, M.M. Filippi and X.J. De Sa, Primary progressive multiple sclerosis, Brain 120(Pt 6) (1997), 1085-1096.
27. S.R. Cohen, B.R. Brooks, R.M. Herndon and G.M. McKhann, A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid, Annals of Neurology 8 (1980), 25-31.
28. J.N. Whitaker, Myelin basic protein in cerebrospinal fluid and other body fluids, Multiple Sclerosis 4 (1998), 16-21.
29. F. Sellebjerg, M. Christiansen, P.M. Nielsen and J.L. Frederiksen, Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis, Multiple Sclerosis 4 (1998), 475-479.
30. D.L. Tirschwell, W.T. Longstreth, Jr., M.E. Rauch-Matthews, W.L. Chandler, T. Rothstein, L. Wray, L.J. Eng, J. Fine and M.K. Copass, Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest, Neurology 48 (1997), 352-357.
31. W.M. Coplin, W.T. Longstreth, Jr., A.M. Lam, W.L. Chandler, T.S. Mayberg, J.S. Fine and H.R. Winn, Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage, Archives of Neurology 56 (1999), 1348-1352.
32. H. Schaarschmidt, H.W. Prange and H. Reiber, Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases, Stroke 25 (1994), 558-565.
33. R.J. Thompson, J.G. Graham, I.N. McQueen, P.A. Kynoch and K.W. Brown, Radioimmunoassay of brain-type creatine kinase-BB isoenzyme in human tissues and in serum of patients with neurological disorders, Journal of the Neurological Sciences 47 (1980), 241-254.
34. K.J. Lamers, B.G. van Engelen, F.J. Gabreels, O.R. Hommes, G.F. Borm and R.A. Wevers, Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders, Acta Neurologica Scandinavica 92 (1995), 247-251.
35. R.T. Cunningham, J.I. Morrow, C.F. Johnston and K.D. Buchanan, Serum neurone-specific enolase concentrations in patients with neurological disorders, Clinica Chimica Acta 230 (1994), 117-124.
36. J.N. Lycke, J.E. Karlsson, O. Andersen and L.E. Rosengren, Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis, Journal of Neurology, Neurosurgery and Psychiatry 64 (1998), 402-404.
37. Y.K. Semra, O.A. Seidi and M.K. Sharief, Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability, Journal of Neuroimmunology 122 (2002), 132-139.
38. A. Petzold, M.J. Eikelenboom, G. Keir, D. Grant, R.H. Lazeron, C.H. Polman, B.M. Uitdehaag, E.J. Thompson and G. Giovannoni, Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. Journal of Neurology, Neurosurgery and Psychiatry 76 (2005), 206-211.
39. E. Silber and M.K. Sharief, Axonal degeneration in the pathogenesis of multiple sclerosis, Journal of the Neurological Sciences 170 (1999), 11-18.
40. M.J. Eikelenboom, A. Petzold, R.H. Lazeron, E. Silber, M. Sharief, E.J. Thompson, F. Barkhof, G. Giovannoni, C.H. Polman and B.M. Uitdehaag, Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy, Neurology 60 (2003), 219-223.
41. R. Ehling, A. Lutterotti, J. Wanschitz, M. Khalil, C. Gneiss, F. Deisenhammer, M. Reindl and T. Berger, Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis, Multiple Sclerosis 10 (2004), 601-606.
42. M. Goedert, M.G. Spillantini and R.A. Crowther, Tau proteins and neurofibrillary degeneration, Brain Pathology 1 (1991), 279-286.
43. M. Goedert, M.G. Spillantini and R.A. Crowther, Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system, Proceedings of the National Academy of Sciences, USA 89 (1992), 1983-1987.
44. E. Kapaki, G.P. Paraskevas, M. Michalopoulou and K. Kilidireas. CSF tau protein is increased in multiple sclerosis, European Journal of Neurology 6(Suppl 3) (1999), 1999.
45. F.J. Jimenez-Jimenez, J.M. Zurdo, A. Hernanz, S. Medina-Acebron, F. de Bustos, B. Barcenilla, Y. Sayed and L. Ayuso-Peralta, Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis, Acta Neurologica Scandinavica 106 (2002), 351-354.
46. M. Colucci, L. Roccatagliata, E. Capello, E. Narciso, N. Latronico, M. Tabaton and G.L. Mancardi, The 14-3-3 protein in multiple sclerosis: a marker of disease severity, Multiple Sclerosis 10 (2004), 477-481.
47. D. Bridges and G.B. Moorhead, 14-3-3 proteins: a number of functions for a numbered protein, Sci STKE 242 (2004), re10.
48. P.F. Boston, P. Jackson and R.J. Thompson, Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders, Lancet Neurology 38 (1982), 1475-1482.
49. A. Martinez-Yelamos, A. Saiz, R. Sanchez-Valle, V. Casado, J.M. Ramon, F. Graus and T. Arbizu, 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis, Neurology 57 (2001), 722-724.
50. J. de Seze, K. Peoc'h, D. Ferriby, T. Stojkovic, J.L. Laplanche and P. Vermersch, 14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis, Journal of Neurology 249 (2002), 626-627.
51. A. Martinez-Yelamos, A. Rovira, R. Sanchez-Valle, S. Martinez-Yelamos, M. Tintore, Y. Blanco, F. Graus, X. Montalban, T. Arbizu and A. Saiz, CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS, Journal of Neurology 251 (2004), 1278-1279.
52. K.L. Kenney, C. Brechtel, K. Takahashi et al., An enzyme-linked immunosorbent assay for the detection of 14-3-3 protein in the cerebrospinal fluid of clinically suspected Creutzfeldt-Jakob disease patients, Annals of Neurology 46 (1999).
53. F. Michetti, A. Massaro and M. Murazio, The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients, Neuroscience Letters 11 (1979), 171-175.
54. F. Michetti, A. Massaro, G. Russo and G. Rigon, The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system, Journal of the Neurological Sciences 44 (1980), 259-263.
55. A. Petzold, M.J. Eikelenboom, D. Gveric, G. Keir, M. Chapman, R.H. Lazeron, M.L. Cuzner, C.H. Polman, B.M. Uitdehaag, E.J. Thompson and G. Giovannoni, Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations, Brain 125 (2002), 1462-1473.
56. L.F. Eng, Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes, Journal of Neuroimmunology 8 (1985), 203-214.
57. M. Noppe, R. Crols, D. Andries and A. Lowenthal, Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology, Clinica Chimica Acta 155 (1986), 143-150.
58. L.E. Rosengren, J. Lycke and O. Andersen, Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit, Journal of the Neurological Sciences 133 (1995), 61-65.
59. E.G. Lund, J.M. Guileyardo and D.W. Russell, cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain, Proceedings of the National Academy of Sciences, USA 96 (1999), 7238-7243.
60. V. Leoni, T. Masterman, F.S. Mousavi, B. Wretlind, L.O. Wahlund, U. Diczfalusy, J. Hillert and I. Bjorkhem, Diagnostic use of cerebral and extracerebral oxysterols, Clinical Chemistry and Laboratory Medicine 42 (2004), 186-191.
61. C.E. Teunissen, C. Dijkstra and C. Polman, Biological markers in CSF and blood for axonal degeneration in multiple sclerosis, Lancet Neurology 4 (2005), 32-41.
62. A.R. Massaro, M. Albrechtsen and E. Bock, N-CAM in cerebrospinal fluid: a marker of synaptic remodelling after acute phases of multiple sclerosis? Italian Journal of Neurological Science (Suppl 6) (1987), 85-88.
63. A.R. Massaro, Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? Multiple Sclerosis 4 (1998), 228-231.
64. A.R. Massaro, C. Soranzo and A. Carnevale, Cerebrospinal-fluid ciliary neurotrophic factor in neurological patients, European Neurology 37 (1997), 243-246.
65. L. Steinman and S. Zamvil, Transcriptional analysis of targets in multiple sclerosis, National Review of Neuroimmunology 3 (2003), 483-492.